Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmNot yet recruitingPhase 22026-03-11NCT07463768

2 results · Page 1 of 1

Swipe the table sideways for more columns.

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Centre Henri BecquerelRouenFrance59
CH côte BasqueBayonneFrance1
CH de PerpignanPerpignanFrance1
Chru BretonneauToursFrance4
Chru De Lille - Hopital Claude HuriezLilleFrance8
CHRU NancyVandœuvre-lès-NancyFrance8
CHU AngersAngersFrance48
CHU BesançonBesançonFrance13
CHU de LimogesLimogesFrance12
Chu de NantesNantesFrance72
CHU de NÎMES - Institut de Cancérologie du GardNîmesFrance2
CHU de Rennes - Hopital PontchaillouRennesFrance3
CHU de TOULOUSE - IUCT ONCOPOLEToulouseFrance1
CHU GrenobleGrenobleFrance19
Chu Henri MondorCréteilFrance7
Gustave RoussyVillejuifFrance48
Hopital d'Instruction des Armées PercyClamartFrance1
Hôpital Haut-LévêquePessacFrance6
Hôpital Lyon-SudPierre-BéniteFrance2
Hôpital Saint LouisParisFrance22